Show simple item record

dc.contributor.authorBlidner, A. G.
dc.contributor.authorChoi, J.
dc.contributor.authorCooksley, Timothy J
dc.contributor.authorDougan, M.
dc.contributor.authorGlezerman, I.
dc.contributor.authorGinex, P.
dc.contributor.authorGirotra, M.
dc.contributor.authorGupta, D.
dc.contributor.authorJohnson, D.
dc.contributor.authorShannon, V. R.
dc.contributor.authorSuarez-Almazor, M.
dc.contributor.authorRapoport, B. L.
dc.contributor.authorAnderson, R.
dc.date.accessioned2020-09-16T11:57:52Z
dc.date.available2020-09-16T11:57:52Z
dc.date.issued2020en
dc.identifier.citationBlidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, et al. Cancer immunotherapy�related adverse events: causes and challenges. Supportive Care in Cancer. 2020.en
dc.identifier.pmid32857220en
dc.identifier.doi10.1007/s00520-020-05705-5en
dc.identifier.urihttp://hdl.handle.net/10541/623228
dc.description.abstractDespite the success and ongoing promise of monoclonal antibody-targeted immune checkpoint inhibitor immunotherapy of advanced malignancies, in particular, antibodies directed against CTLA-4 and PD-1/PD-L1, the development of immune-related adverse events (irAEs) remains a constraint of this type of therapy. Although rarely fatal, the occurrence of irAEs may necessitate discontinuation of immunotherapy, as well as administration of corticosteroids or other immunosuppressive therapies that may not only compromise efficacy but also predispose for development of opportunistic infection. Clearly, retention of efficacy of immune checkpoint-targeted therapies with concurrent attenuation of immune-mediated toxicity represents a formidable challenge. In this context, the current brief review examines mechanistic relationships between these events, as well as recent insights into immunopathogenesis, and strategies which may contribute to resolving this issue. These sections are preceded by brief overviews of the discovery and functions of CTLA-4 and PD-1, as well as the chronology of the development of immunotherapeutic monoclonal antibodies which target these immune checkpoint inhibitors.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00520-020-05705-5en
dc.titleCancer immunotherapy-related adverse events: causes and challengesen
dc.typeArticleen
dc.contributor.departmentLaboratory of Immunopathology, Institute of Biology and Experimental Medicine-CONICET, Buenos Aires, Argentina.en
dc.identifier.journalSupportive Care in Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record